A lung cancer diagnostic marker and its application
By discovering and using the TMEM82 gene as a marker for lung cancer diagnosis, combining detection primers and kits, the problem of insufficient sensitivity and specificity of lung cancer diagnosis markers in the prior art is solved, and a high sensitivity and high specificity diagnosis of lung cancer is achieved. Significant clinical and economic value.
Patent Information
- Application Number
- CN202410622759.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-05-20
- Publication Date
- 2024-11-01
- Estimated Expiration
- 2044-05-20
AI Technical Summary
Existing diagnostic markers for lung cancer are insufficient in terms of sensitivity and specificity, making it difficult to provide more accurate and rapid diagnostic methods, especially in early detection and pathological classification.
By comparing the differences in gene expression between lung cancer patients and healthy people, the TMEM82 gene was found as a diagnostic marker for lung cancer, and corresponding detection primers and detection kits were designed to quickly identify lung cancer.
The diagnostic marker of TMEM82 lung cancer is highly expressed in lung cancer tissues. Inhibition of this gene can affect the proliferation, migration and invasion of lung cancer cells. The test results show that the sensitivity is 80.0% and the specificity is 85%. It is easier to detect with CT and is of great importance. clinical and economic value.
Smart Images

Figure CN118460716B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical diagnosis, and in particular to a lung cancer diagnostic marker and application thereof. Background Art
[0002] Lung cancer is divided into two major categories according to histopathology: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with the former accounting for about 85%. Compared with patients receiving standard chemotherapy, patients with stage IV NSCLC who have EGFR sensitive mutations will have significantly improved progression-free survival and overall survival after using epidermal growth factor receptor-tyrosine kinase inhibitors. Squamous cell lung cancer is insensitive to chemotherapy and radiotherapy and only responds to surgery. Small cell lung cancer has the highest degree of malignancy, the worst prognosis, and is prone to recurrence and distant metastasis. These two pathological subtypes provide fewer options for previously described systemic treatments. Early detection and pathological classification of lung cancer can help patients receive the most timely and effective treatment, improve survival rate and reduce death.
[0003] Tumor markers (TM) generally refer to biological substances synthesized and released by tumor cells, or substances produced by the body in response to tumor tissue. Substances that can exist in cells, tissues or body fluids, can be quantified by chemical or immunological methods, can confirm the existence of cancer (or exist in a certain organ), and can monitor tumor treatment and prognosis. These substances must not exist in normal people or appear at levels significantly higher than normal people in cancer patients. Lung cancer tumor markers include carcinoembryonic antigen CEA, squamous cell carcinoma antigen SCC, cytokeratin CYFRA21-1, which are common in non-small cell lung cancer (NSCLC), and neuronal enolase NSE and pro-gastrin releasing peptide ProGRP, which are common in small cell lung cancer (SCLC). In 2019, the Chinese Medical Association's Respiratory Diseases Branch compiled and published the "Chinese Expert Consensus on Lung Cancer Screening and Management": Seven autoantibodies for lung cancer are important technologies for lung cancer screening and early diagnosis. The 2020 lung health management expert consensus recommends the use of a "dual screening" model of low-dose spiral CT (LDCT) and lung cancer autoantibodies for opportunistic screening of lung cancer and risk stratification of lung nodules.
[0004] Detection of seven autoantibodies for lung cancer Enzyme-linked immunosorbent assay is used to qualitatively detect the concentrations of seven autoantibodies (p53, GAGE 7, PGP9.5, CAGE, MAGE Al, SOX2, GBU4-5) in human serum in vitro. Combined detection with CT and detection of lung cancer tumor markers can improve the positive predictive value of lung cancer.
[0005] However, the above 7 markers obviously need to be detected in conjunction with CT. This application will explore lung cancer markers with higher sensitivity and higher specificity to provide a new direction for lung cancer diagnosis. Summary of the invention
[0006] In order to solve the above problems, the present invention compares the gene expression differences between lung cancer patients and healthy people, so as to find suitable candidate lung cancer diagnostic markers as diagnostic markers for lung cancer.
[0007] The first object of the present invention is to provide a diagnostic marker for lung cancer, wherein the diagnostic marker is TMEM82.
[0008] The second object of the present invention is to provide a primer pair for detecting the above-mentioned lung cancer diagnostic marker, wherein the primer pair sequence is SEQ ID NO: 1 to SEQ ID NO: 2.
[0009] The third object of the present invention is to provide a detection kit for lung cancer, wherein the kit comprises primers.
[0010] The fourth object of the present invention is to provide the use of the above-mentioned lung cancer diagnostic marker in the preparation of a reagent for detecting lung cancer.
[0011] The fifth object of the present invention is to provide the use of the above primers in preparing a kit for detecting lung cancer.
[0012] The sixth object of the present invention is to provide the use of the above-mentioned lung cancer diagnostic marker in detecting lung cancer, wherein the use is for non-diagnostic purposes.
[0013] Compared with the prior art, the present invention has at least the following beneficial effects:
[0014] The lung cancer diagnostic marker of the present invention is highly expressed in the corresponding lung cancer tissue and lung cancer cell line. The results of the gene silencing experiment prove that inhibiting the gene can affect the proliferation, migration and invasion of lung cancer cells. The expression amount of the lung cancer diagnostic marker is used as a detection variable to judge the diagnosis result. The ROC curve results show that AUC=0.806 (0.706-0.906), the sensitivity is 80.0%, the specificity is 85%, and the p value is <0.001, indicating that the TMEM82 lung cancer diagnostic marker can be used as a diagnostic marker for lung cancer. It can quickly and accurately diagnose lung cancer, has strong specificity and high sensitivity. The primers and kits developed based on the lung cancer diagnostic marker can quickly identify lung cancer, and combined with the existing protein markers for CT detection, it is more convenient and has great clinical value and economic value. BRIEF DESCRIPTION OF THE DRAWINGS
[0015] Figure 1 Expression of TMEM82 in lung cancer tissues and normal tissues.
[0016] Figure 2 TMEM82 expression in lung cancer cell lines and normal cell lines.
[0017] Figure 3Effects of different siRNAs on the expression of TMEM82 in lung cancer cell lines.
[0018] Figure 4 Effect of TMEM82 on lung cancer cell proliferation.
[0019] Figure 5 Effect of TMEM82 gene on migration of lung cancer cells.
[0020] Figure 6 Effect of TMEM82 gene on invasion of lung cancer cells.
[0021] Figure 7 ROC curve of TMEM82 for lung cancer detection. DETAILED DESCRIPTION
[0022] In order to make the technical problems, technical solutions and advantages to be solved by the present invention more clear, a detailed description will be given below with reference to the accompanying drawings and specific embodiments.
[0023] Example 1 Screening for lung cancer diagnostic markers related to lung cancer
[0024] 1. Sample collection
[0025] Ten non-small cell lung cancer tissues and corresponding adjacent normal tissue samples were collected from the cooperative hospital and sent to BGI for high-throughput sequencing. All patients gave informed consent, and the acquisition of all the above specimens was approved by the organizational ethics committee of the cooperative hospital.
[0026] 2. Tissue RNA was extracted using a tissue RNA extraction kit (QIAGEN).
[0027] 3. The RNA extracted above was subjected to agarose gel electrophoresis, and the concentration and purity of the extracted RNA were detected using Nanodrop2000. The results met the library construction standards.
[0028] 4. Remove ribosomal RNA from total RNA.
[0029] 5. Use Illumina TruseqTM RNA sample Prep Kit to construct cDNA library.
[0030] 6. Sequence the cDNA library using the Illumina X-Ten sequencing platform.
[0031] 7. Perform bioinformatics analysis on high-throughput transcriptome sequencing data and screen out the TMEM82 gene with the most significant expression difference as a candidate diagnostic marker for lung cancer.
[0032] Example 2 QPCR sequencing to verify the differential expression of TMEM82 gene
[0033] 1. Use the cancer tissue samples and adjacent tissue samples from 10 patients collected previously to perform large-sample QPCR verification of the differential expression of the TMEM82 gene.
[0034] 2. The RNA extraction procedure is the same as in Example 1.
[0035] 3. Reverse transcription:
[0036] 1 μg of total RNA template was mixed with 2 μL 10× buffer, 2 μL dATP (10 mM), 0.5 μL polyA polymerase, 0.5 μL ribonuclease inhibitor, and RNase-free ddH2O to make up the total volume to 20 μL, and incubated at 37°C for 1 h; then 1 μL 0.5 μg / μL Oligo (dT) specific RT primer was added to the reaction tube, incubated at 70°C for 5 min, and immediately incubated on ice for at least 2 min, and then the reaction mixture was mixed with 4 μL 5× buffer, 1 μL dNTP (10 mM), 0.5 μL M-MLV reverse transcriptase, 0.5 μL ribonuclease (RNase) inhibitor, 10 μL polyA reaction mixture and 4 μL RNase-free ddH2O, and incubated at 42°C for 1 h.
[0037] 4. QPCR amplification test
[0038] QPCR amplification primers were designed based on the coding sequences of TMEM82 gene and GAPDH gene in Genebank and synthesized by GenScript Biotechnology. The specific primer sequences are as follows:
[0039] 1) Primer design:
[0040] The primer sequences for the TMEM82 gene are:
[0041] Forward primer: 5'-CAGAGGCCTCCAGTGTCAAC-3' (SEQ ID NO. 1);
[0042] Reverse primer: 5'-AAGAAAGTTGGCAAAGAGGGGG-3' (SEQ ID NO. 2);
[0043] Primer sequences for GAPDH:
[0044] Forward primer: 5'-GCTCCCTCTTTCTTTGCAGC-3' (SEQ ID NO. 3);
[0045] Reverse primer: 5'-TGAGTCCTTCCACGATACCAA-3' (SEQ ID NO. 4);
[0046] 2) Reaction system
[0047] SYBR Green polymerase chain reaction system 12.5 μL, forward and reverse primers (5 μM) 1 μL each, template cDNA 2.0 μL, ddH2O 8.5 μL.
[0048] 3) Reaction conditions
[0049] 95℃10min, (95℃15s, 60℃60s)×45 cycles. SYBR Green was used as a fluorescent marker, and the PCR reaction was performed on a Light Cycler fluorescent quantitative PCR instrument. GAPDH was used as a reference gene, and the target band was determined by melting curve analysis and electrophoresis. ΔΔ The relative quantification was performed by CT method.
[0050] 5. Results
[0051] The results are as follows Figure 1 As shown, the expression level of TMEM82 gene was upregulated in lung cancer tissue (P<0.05); the results showed that the lung cancer diagnostic marker TMEM82 can be used as a potential diagnostic marker for lung cancer.
[0052] Example 3 Differential expression of TMEM82 gene in cell lines
[0053] 1. Cell culture
[0054] Human lung cancer cell line A549 cells (purchased from ATCC) and human normal lung cells HLF-a (purchased from ATCC) were cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and placed in a 5% CO2, 37°C cell culture incubator for routine culture. The medium was changed every 2-3 days. The cells were passaged whenever the cell confluence reached 90%, and the cells in the logarithmic growth phase were used for subsequent experiments.
[0055] 2. RNA extraction, reverse transcription, and QPCR are the same as in Example 2
[0056] The results are as follows Figure 2 As shown, TMEM82 gene expression was upregulated in lung cancer cells (P<0.05).
[0057] Example 4 Silencing of TMEM82 gene
[0058] 1. Human lung cancer cell line A549 cells were cultured in DMEM medium containing 10% fetal bovine serum, 1% penicillin and streptomycin, and placed in a 5% CO2, 37°C cell culture incubator for routine culture. The medium was changed every 2-3 days. Cells were passaged when the cell confluence reached 90%, and cells in the logarithmic growth phase were used for subsequent experiments.
[0059] 2. siRNA Design
[0060] siRNA was designed against the sequence of TMEM82 gene. The designed siRNA sequence is as follows:
[0061] Si-TMEM82#1:
[0062] Sense strand: 5'-UGGAAAAUCCUGUAUCUGGCA-3' (SEQ ID NO. 5),
[0063] Antisense strand: 5'-CCAGAUACAGGAUUUUCCAUC-3' (SEQ ID NO. 6);
[0064] Si-TMEM82#2:
[0065] Sense strand: 5'-AUGGAAAAUCCUGUAUCUGGC-3' (SEQ ID NO. 7),
[0066] Antisense strand: 5'-CAGAUACAGGAUUUUCCAUCC-3' (SEQ ID NO. 8);
[0067] Human lung cancer cell line A549 cells were seeded in a six-well plate at a density of 200,000 / well, and transfection was performed when the cells adhered to the wall and grew to about 50%-60% fusion.
[0068] The experiment was divided into a blank control group (human lung cancer cell line A549 cells), a negative control group (siRNA-NC) and an experimental group (20nM) (Si-TMEM82#1, Si-TMEM82#2). The siRNA in the negative control group had no homology with the sequence of the TMEM82 gene, and the concentration was 20nM / well. Transfection was performed simultaneously.
[0069] 2. QPCR detected the expression level of TMEM82 gene. The results are as follows Figure 3 The results showed that all experimental groups were able to reduce the expression level of TMEM82.
[0070] Example 5 Cell experiment
[0071] 1. Cell culture and transfection are the same as in Example 4.
[0072] 2) Take the amount of liquid added to one well of a six-well plate as an example:
[0073] Solution A: 5 μL of siRNA mixed with 195 μL of OPTI-MEM (purchased from Gibco);
[0074] Solution B: 5 μL of DharmaFECT and 195 μL of OPTI-MEM (purchased from Gibco) were mixed;
[0075] After standing at room temperature for 5 minutes, mix solution A and solution B evenly, and then stand at room temperature for 20 minutes to prepare the working solution. Do not mix vigorously afterwards. Add 1.6 ml of culture medium to the six-well plate and then slowly add 400 μL of the above working solution dropwise to avoid excessive stimulation to the cells.
[0076] 3) Add 100 μL of the mixture to each well of the cell plate and gently shake the cell plate back and forth to mix the mixture with the culture medium in the well.
[0077] 4) Culture in a CO2 incubator at 37°C for 48 hours and detect the knockdown efficiency.
[0078] 2. Cell proliferation assay, the following experimental steps were repeated three times:
[0079] 1) With a cell density of 5x10 3 / well, inoculated in 96-well plates, 100 μL per well, and 3 replicate wells were set up for each group.
[0080] 2) After the cells are completely attached, transfection is performed according to the above steps. CCK8 detection is performed at 0h, 24h, 48h, 72h, and 96h after transfection. The CCK8 solution is replaced, and the cells are incubated at 37°C for 2h in the dark. The absorbance at a wavelength of 450nm is measured using an enzyme marker. Figure 4 , indicating that inhibiting TMEM82 expression can significantly inhibit the proliferation of lung cancer cells.
[0081] Transwell chambers were used for cell migration analysis, and matrix gel-coated Transwell chambers were used for invasion analysis. The pore size was 0.8 μm. The cell lines of the control group and experimental group were resuspended in serum-free culture medium and inoculated into the chambers (about 3×10 4 cells / well) and cultured for the appropriate time according to the characteristics of the cells. The cells that did not pass through the holes in the upper layer of the chamber were removed with a cotton swab. The cells that passed through the membrane in the lower layer were fixed with methanol for 15 minutes and stained with 0.1wt% crystal violet for 20 minutes and observed under a microscope. Five fields of view were randomly observed and the number of cells that passed through the membrane was counted. The results are shown in Figure 5-Figure 6 As shown, inhibition of TMEM82 expression can significantly inhibit the migration and invasion of lung cancer cells.
[0082] Example 6 ROC detection
[0083] Cancer tissues from 40 lung cancer patients and lung tissue samples from 40 normal healthy people were collected again to verify the diagnostic effect of TMEM82. The expression of TMEM82 was used as a detection variable to judge the diagnostic results. Analysis method: The ROC of the indicator was analyzed using MedCalc Statistical Software version software. The ROC curve results showed that AUC=0.806 (0.706-0.906), sensitivity was 80.0%, specificity was 85%, and p value <0.001. The above results show that TMEM82 lung cancer diagnostic marker can be used as a diagnostic marker for lung cancer.
[0084] The above is a preferred embodiment of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.
Claims
1. Use of a detection primer pair for lung cancer diagnostic markers in the preparation of a lung cancer detection kit, characterized in that: The lung cancer diagnostic marker is TMEM82.
2. The use according to claim 1, characterized in that The primer pair sequences are 5′-CAGAGGCCTCCAGTGTCAAC-3′; and 5'-AAGAAAGTTGGCAAAGAGGGGG-3'.
